Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: repair and antimicrobial signaling research
This entry is a multi-compound blend. Each component can be opened individually in the reconstitution calculator.
Component amounts shown are arithmetic starters based on equal distribution. Edit values in the calculator before saving.
LL-37 is an endogenous antimicrobial peptide with dose-, tissue-, and formulation-dependent immunologic effects. A Phase 2b trial studied topical LL-37 in venous leg ulcers and did not meet the primary healing comparison in the full cohort. No study evaluates LL-37 co-formulated with BPC-157 and TB-500, and current searches did not establish a standardized fixed triple product.
Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.
Data source: LL-37 human trial, FDA safety materials, and targeted current-market search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
The previous 5 mg and 10 mg sizes were ambiguous and not verified as a fixed triple blend. Retain only as a conceptual/community record with a human-decision flag.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.